Highlights: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Read more

LAuRA - Powered by PAT

Making future diagnostics affordable,
accessible and available anywhere

What We Do

LamdaGen develops and commercializes innovative detection technologies wherever and whenever time-critical detection is needed.

We focus on developing advanced testing systems that are simple, cost effective and globally available.

Our One Health (cdc.gov/onehealth) approach involves innovative systems for Human Clinical, Food & Water Safety and Animal Health.

Each unique system is built on the LAuRA™ Digital Detection platform, powered by PAT™.

The LAuRA Digitial Detection Platform, powered by PAT

See how Plasmonic Amplification Technology enables high sensitivity detection with the speed and precision to transform and improve Point of Care testing.

Features

Fast Results

High-Sensitivity-Icon1

High Sensitivity

Patented Technology

Easy to Integrate

Easy to Use

LAuRA POC System

The LAuRA Digital Detection platform that combines the speed and simplicity of current rapid lateral flow assays with the sensitivity and quantitation of microtiter plate assays.

The LAuRA POC System delivers laboratory quality results equivalent to gold standard ELISA’s in minutes rather than hours. LAuRA’s test procedure is simple and easy to use. Disposable cartridges can run single or dual tests simultaneously and deliver precise results in less than 15 minutes.

Leveraging the inherent properties of advanced nano-based plasmonics, the LAuRA immuno-based platform provides high sensitivity detection capabilities far exceeding those of existing rapid assays. The patented platform is flexible and scalable, enabling uniquely powerful detection systems ranging from small benchtops to handhelds to throughput. 

Innovative LAuRA systems will be developed for applications in Human Health, Animal Health and Food & Water Safety.

What would you like to learn?

Technology

LAuRA, powered by PAT harnesses the unique properties of plasmonics to revolutionize diagnostic detection

Applications

See how LAuRA delivers results with speed, sensitivity and convenience like no other platform

About Us

LamdaGen is taking a One Health approach to improve the performance and accessibility of rapid testing

Latest News

LamdaGen Corporation receives Grant Notification from Indian Patent Office for Patent Number 360405, ENZYMATIC ASSAY FOR LSPR
LamdaGen Corporation receives Grant Notification from Indian Patent Office for Patent Number 360405, ENZYMATIC ASSAY FOR LSPRMarch 11, 2021
Read More
LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the Indian Patent Office has granted and recorded patent 360405 titled ENZYMATIC ASSAY FOR LSPR which enables
LamdaGen Corporation receives Official Notice from the USPTO of Allowance of Patent: DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITY
LamdaGen Corporation receives Official Notice from the USPTO of Allowance of Patent: DIGITAL LSPR FOR ENHANCED ASSAY SENSITIVITYJanuary 18, 2021
Read More
MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice
LamdaGen Corporation receives Official Notice of Allowance from the Japanese Patent Office for issuance of patent: MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS
LamdaGen Corporation receives Official Notice of Allowance from the Japanese Patent Office for issuance of patent: MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORSJanuary 8, 2021
Read More
MENLO PARK, CA, January 8, 2021— LamdaGen Corporation, a developer of plasmonic biosensor systems for diagnostics, announced the Japanese Patent Office has given Official Notice of Allowance to its patent application entitled MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS which enables high
A Breakdown of the Reported Sensitivities of SARS-CoV-2 Diagnostic Assays and Implications for the Sensitivity Required for Rapid Antigen Tests
A Breakdown of the Reported Sensitivities of SARS-CoV-2 Diagnostic Assays and Implications for the Sensitivity Required for Rapid Antigen TestsOctober 14, 2020
Read More
The viral load of SARS-CoV-2 in patients charted as determined in hospital settings across several regions of the world.[1-4] In three studies, the pool includes a limited number patients with mild to moderate symptoms in hospitals,
Previous
Next

Interested in exploring partnerships with us?

LamdaGen is focused on providing innovative detection technologies wherever and whenever they are needed. Contact us to discuss how we can partner to improve testing globally.